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To the Editor:
We thank Kratz et al. for their constructive comments which
are mostly focused on the differences with the guidelines
elaborated in the framework of an international consortium
coordinated by Canadian and US teams in 2017 [1].
In medical genetics, the paradigm of cystic fibrosis and
CFTR-related disorders has shown that it may be appropriate,
not only for health professionals but also for patients, to
expand the definition of a syndrome to a wider molecularly
based definition, in order to highlight the diversity of phe-
notypes associated with germline variants. Therefore, we
think that it is indeed appropriate to expand the Li–Fraumeni
syndrome (LFS) toward to a wider and molecularly based
cancer predisposition syndrome, designated heritable TP53-
related cancer syndrome. We agree that the recommendation
of testing patients presenting only jaw osteosarcoma is so far
not supported by published articles but only, as we indicated
[2], on the experience of certain centres. Whereas we con-
sidered that it was not justified at the present time to sys-
tematically test all children with osteosarcoma (the mutation
detection rate being estimated up to 3.8% [3]), the recurrent
identification of germline disease-causing TP53 variants in
patients with jaw osteosarcoma, an infrequent location as
compared to long bones, lead us to formulate this recom-
mendation. It seems that our colleagues have overinterpreted
the statement “Testing for disease-causing TP53 variants
should be performed before starting treatment in order to
avoid in variant carriers, if possible, radiotherapy and geno-
toxic chemotherapy and to prioritize surgical treatments.” We
fully agree that, in cancer patients carrying disease-causing
TP53 variants, the first priority is to effectively treat the
tumours but we believe that a multidisciplinary team should
discuss the risks of recurrence and subsequent primary
tumours before the initiation of treatment and choose the best
therapy. For instance, after identification of a germline TP53
disease-causing variant in a young woman with invasive,
T1N0 breast cancer mastectomy should be offered instead of
breast-conserving surgery followed by radiotherapy. The
previously published guidelines [1] recommend performing
(in all germline TP53 variant carriers), a medical follow-up
including annual whole-body MRI (WBMRI) and brain MRI
starting from the first year of age, independently of the per-
sonal and medical history and type of TP53 variant. However,
we must now recognize that the global penetrance of germline
TP53 variants has been overestimated, likely depending on so
far unrecognized modifying factors. More importantly, we
must be aware that only a minor fraction of germline TP53
variant carriers worldwide, and in particular in the USA, have
currently access to this intensive protocol. In our guideline,
we advocate for a stratified strategy, by recommending pre-
symptomatic testing and the intensive protocol in childhood
from birth, under the following conditions: “the index case
has developed a childhood cancer; or childhood cancers have
been observed within the family; or this variant has already
been detected in other families with childhood cancers; or this




1 Department of Genetics, Rouen University Hospital and Inserm
U1245, Normandy Centre for Genomic and Personalized
Medicine, Normandie University, UNIROUEN, Rouen, France
2 Hereditary Cancer Unit, Department of Clinical Genetics,
Karolinska University Hospital, Stockholm, Sweden
3 i3S—Instituto de Investigação e Inovação em Saúde & Institute of
Molecular Pathology and Immunology of the University of Porto,
and Porto Comprehensive Cancer Center, Porto, Portugal
4 Community Representative, Berlin, Germany
5 Division of Evolution and Genomic Sciences, Manchester Centre
for Genomic Medicine, University of Manchester, MAHSC, St
Mary’s Hospital, Manchester University Hospitals NHS
Foundation Trust, Manchester, UK
















variant corresponds to a dominant-negative missense variant.”
However, we also carefully open the door by indicating that
testing children in families with only early-onset adult cancers
can be considered, but only after careful discussion with the
parents in order to address the burden, and uncertain benefits,
of surveillance in childhood [2]. Our colleagues consider that
the surveillance interval that we propose in children for the
detection of adrenocortical carcinoma is too long, compared
to the interval previously recommended (6 vs. 3–4 months).
They may be right (especially until the age 5, probably not
above the age 10), but we are not aware of studies demon-
strating the additional value of performing a follow-up every
3–4 months. All the studies, except one, published so far and
reporting the efficiency in TP53 variant carriers of WBMRI,
in terms of tumour detection rate, have been performed
without Gadolinium enhancement, which leads to this
recommendation [2]. In females with germline disease-
causing TP53 variants, breast cancer risk increases sig-
nificantly after the second decade with a peak between 30–44
years and cumulative risk reaches a plateau before 60 [4–6].
Therefore, we think that it is appropriate to fix an age limit for
breast MRI at 65 years. A recent review on brain tumours in
TP53 variant carriers has confirmed that brain tumours pre-
sent a bimodal distribution with the highest peak in young
children before 5 years of age and a small peak in adults
observed between the third and fourth decades. This supports
our proposal to perform brain MRI until 50 years [7]. Finally,
we confirm that the studies, which had suggested that color-
ectal cancer (CRC) is associated with germline TP53 variants,
suffer from certain limitations: the first [8] reported in a series
of 397 patients, from 64 LFS families, 16 cases of CRC (4%).
The lifetime risk for CRC is estimated in the general popu-
lation to 4%. Furthermore, among the patients with CRC, the
majority had not been tested themselves but were first- or
second-degree relatives of TP53 variant carriers. In a second
article [9], the authors reported in a series of 467 patients with
CRC at age 40 years or younger, six germline TP53 variants
but examination of these variants, based on the current clas-
sification criteria, shows that only two out of the six variants
meet criteria for being classified as a class 4 or 5 variant. A
third study [10] reported colorectal tumours in 8 among 93
patients with germline TP53 variants (8.6%), but the authors
did not provide data on TP53 variants. As cancer geneticists
and oncologists, we highlight that the risk of overloading the
medical follow-up in high genetic risk individuals is to alter
the compliance of the patients.
In conclusion, we do not think that the European guide-
lines elaborated by the ERN GENTURIS, that have been
developed with an active participation of patient representa-
tives [2], are in opposition to the guidelines previously pub-
lished [1]. They instead constitute a stratified version of the
previous ones, which may be easier to implement in different
countries for patient benefits.
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